Maxtar Bio-Genics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.91 M
as on 24-10-2024
- Company Age 21 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.50 M
as on 24-10-2024
- Revenue -80.75%
(FY 2023)
- Profit -110.94%
(FY 2023)
- Ebitda -83.45%
(FY 2023)
- Net Worth -2.39%
(FY 2023)
- Total Assets -38.18%
(FY 2023)
About Maxtar Bio-Genics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.91 M.
The company currently has active open charges totaling ₹1.50 M.
Madan Bansal and Jagdish Bansal serve as directors at the Company.
- CIN/LLPIN
U24239DL2003PTC121514
- Company No.
121514
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jul 2003
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Maxtar Bio-Genics Private Limited offer?
Maxtar Bio-Genics Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup.
Who are the key members and board of directors at Maxtar Bio-Genics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madan Bansal  | Director | 01-Jan-2005 | Current |
| Jagdish Bansal | Director | 29-Jul-2003 | Current |
Financial Performance of Maxtar Bio-Genics.
Maxtar Bio-Genics Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 80.75% decrease. The company also saw a substantial fall in profitability, with a 110.94% decrease in profit. The company's net worth dipped by a decrease of 2.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Maxtar Bio-Genics?
In 2023, Maxtar Bio-Genics had a public holding of 10.99%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Uni-Pex Pharmaceuticals Private LimitedActive 25 years 9 monthsMadan Bansal and Jagdish Bansal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 09 Jul 2021 | ₹1.50 M | Open |
How Many Employees Work at Maxtar Bio-Genics?
Unlock and access historical data on people associated with Maxtar Bio-Genics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maxtar Bio-Genics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maxtar Bio-Genics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
